Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

The National Institutes of Health (NIH) is seeking applications for the early stage testing of pharmacologic or device-based interventions for the treatment of mental disorders. This funding opportunity announcement (FOA) encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. The goal of this initiative is to support early stage testing of therapeutic interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested. • The FOA is intended to support early stage testing of pharmacologic or device-based interventions. • The intervention should have a novel mechanism of action. • The study should generate information about the mechanisms underlying a disorder or an intervention response. • The study should provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.